Navigation Links
Video: FDA States Consumers Should Continue to Use alli
Date:9/2/2009

PARSIPPANY, N.J., Sept. 2 /PRNewswire/ -- The following is an updated GlaxoSmithKline Consumer Healthcare statement in response to the FDA's Early Communication about the safety review of orlistat:

On August 24th the FDA reported that it is continuing its safety review of orlistat and liver-related serious adverse events.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/alli/39949/

It's important consumers know that alli is safe and effective and there's no evidence to suggest alli causes liver injury. In fact, the FDA has said that consumers should continue to use alli as directed.

Because orlistat is minimally absorbed in the blood and works locally in the gastro-intestinal tract, there is no obvious biological mechanism to suggest liver injury can occur with alli.

To put FDA's communication into perspective, there is a high prevalence of liver disease in people who are overweight. It is estimated that about 15-20% of obese people have liver injury due to excessive fat in the liver.[1] Additionally, in obese individuals, gradual weight loss can prevent injury or improve liver function.

The August 24th communication is part of FDA's current process of sharing information directly with consumers and healthcare professional related to the safety monitoring of marketed drug products. This does not mean that FDA has concluded that there is a risk.

Since orlistat first became available as a prescription medicine in 1998, more than 40 million people have used the drug. Of these, more than 6 million have used alli, the only FDA-approved over-the-counter weight loss product. The FDA identified two reports of liver injury out of the six million consumers who have used alli since its approval in 2007.

Orlistat, the active ingredient in alli, is the most-studied weight loss medicine. Its safety has been established through 100 clinical studies involving more than 30,000 patients.

GSK continues to proactively monitor the safety of orlistat and share all relevant information with regulatory agencies. Based on our comprehensive review of the safety data from preclinical and clinical, post-marketing safety surveillance, published literature as well as epidemiology data, we conclude that the data do not suggest that orlistat is causally related to liver injury.

We are actively working with the FDA to better understand the reports it has received. If you have concerns, you should talk to your doctor or pharmacist. For more information on the safety and efficacy of alli, please visit www.myalli.com and/or call 1-800-671-2554.

[1] Preiss, D., Sattar, N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. (2008) Clinical Science, 115 (5-6), pp. 141-150.

    FOR ACCESS TO EXPERT COMMENT:
    Malesia Dunn
    malesia.a.dunn@gsk.com
    412-200-3544

    Mechal Weiss
    mechal.weiss@edelman.com
    212-642-7731
    917-952-4807


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Renowned Health Expert Dra. Aliza Teams Up With Baby Looney Tunes To Promote Healthy, Happy Babies
2. Video: Life Insurance Awareness Month is the Ideal Time for an Insurance Review
3. Video: Physical and Mental Health of U.S. Warfighter Is Focus of Military Health Research Forum
4. Video: Project Runway Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma
5. Video: New Insights Link Low HDL-Cholesterol and Elevated Triglycerides with Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
6. Video: HHS Launches Best Bones Forever!
7. Video: CVS/pharmacy and MinuteClinic Encourage Americans to Protect Themselves Early With a Seasonal Flu Shot
8. Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients
9. Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients
10. Video: AstraZeneca Traveling Exhibit Helps Americans Understand and Manage Bipolar Depression
11. Video: School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: